ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.38
0.74%
US Tech 100
20,836.00
1.31%
S&P 500
5,930.85
1.09%
US Dollar vs CAD
1.43421
0.00%
Bitcoin
96,296.15
-0.93%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Tango Therapeutics Inc (TNGX) Share Price

Tango Therapeutics Inc

Tango Therapeutics Inc (TNGX)

NASDAQ
3.10
0.16
(5.44%)
Closed December 22 3:00PM
Delayed by 15 minutes
3.00
-0.10
(-3.23%)
After Hours: 4:24PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
3.00
Bid
3.00
Ask
3.50
Volume
2,810,897
2.86 Day's Range 3.13
2.70 52 Week Range 13.005
Market Cap
322.253M
Previous Close
2.94
Open
2.91
Last Trade
1
@
3.2
Last Trade Time
Financial Volume
US$ 8,444,630
VWAP
3.0042
Average Volume (3m)
1,965,491
Shares Outstanding
107,417,818
Dividend Yield
-
PE Ratio
-3.27
Earnings Per Share (EPS)
-0.95
Revenue
36.53M
Net Profit
-101.74M

About Tango Therapeutics Inc

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.tangotx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Tango Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TNGX. The last closing price for Tango Therapeutics was US$2.94. Over the last year, Tango Therapeutics shares have traded in a share price range of US$ 2.70 to US$ 13.005.

Tango Therapeutics currently has 107,417,818 shares outstanding. The market capitalization of Tango Therapeutics is US$315.81 million. Tango Therapeutics has a price to earnings ratio (PE ratio) of -3.27.

Ask ADVFN Intelligence (AI)

TNGX Latest News

More News

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that...

December 03 2024
Business Wire

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that...

November 27 2024
Business Wire

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

November 20 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

November 18 2024
Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

November 07 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

November 06 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 06 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 06 2024
Edgar (US Regulatory)

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

– Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into full development with multiple combination studies – – Clinical collaboration...

November 06 2024
Business Wire

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

– TNG462 demonstrated durable clinical activity across multiple tumor types, including non-small cell lung cancer (NSCLC) and pancreatic cancer, in ongoing phase 1/2 clinical trial, moving into...

November 06 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.155.263157894742.853.292.725186072.95240911CS
4-0.59-16.434540393.594.212.714625583.30065025CS
12-4.4-59.45945945957.47.782.719654914.15990878CS
26-6.69-69.0402476789.6912.0152.713994715.98034786CS
52-7.22-70.645792563610.2213.0052.710222356.9895005CS
156-7.94-72.577696526510.9413.032.477107867.14218803CS
260-6.61-68.78251821029.6118.842.476567657.36314121CS

TNGX - Frequently Asked Questions (FAQ)

What is the current Tango Therapeutics share price?
The current share price of Tango Therapeutics is US$ 3.00
How many Tango Therapeutics shares are in issue?
Tango Therapeutics has 107,417,818 shares in issue
What is the market cap of Tango Therapeutics?
The market capitalisation of Tango Therapeutics is USD 315.81M
What is the 1 year trading range for Tango Therapeutics share price?
Tango Therapeutics has traded in the range of US$ 2.70 to US$ 13.005 during the past year
What is the PE ratio of Tango Therapeutics?
The price to earnings ratio of Tango Therapeutics is -3.27
What is the cash to sales ratio of Tango Therapeutics?
The cash to sales ratio of Tango Therapeutics is 9.12
What is the reporting currency for Tango Therapeutics?
Tango Therapeutics reports financial results in USD
What is the latest annual turnover for Tango Therapeutics?
The latest annual turnover of Tango Therapeutics is USD 36.53M
What is the latest annual profit for Tango Therapeutics?
The latest annual profit of Tango Therapeutics is USD -101.74M
What is the registered address of Tango Therapeutics?
The registered address for Tango Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Tango Therapeutics website address?
The website address for Tango Therapeutics is www.tangotx.com
Which industry sector does Tango Therapeutics operate in?
Tango Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.91M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.75M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.94M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
9.27M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
6.25M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
281.23M

TNGX Discussion

View Posts
Monksdream Monksdream 6 months ago
TNGX under $10
👍️0
Monksdream Monksdream 8 months ago
TNGX under $10
👍️0
bikaver bikaver 1 year ago
Stopped out with small loss.
👍️0
bikaver bikaver 1 year ago
TNGX......Holding up well, but will tumble soon.
👍️0
bikaver bikaver 1 year ago
TNGA.....short @ 8.60 This is the strength that I wanted to see!
👍️0
bikaver bikaver 1 year ago
TNGX.....Studying the TNGX chart this evening. I'll short it at a good sign of strength if the opportunity presents itself tomorrow.
👍️0
SmokeSignals SmokeSignals 1 year ago
up $4>H.C. Wainwright Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)AUGUST 8, 2023TIPRANKS
Barclays Releases a Buy Rating on Tango Therapeutics (TNGX)AUGUST 8, 2023TIPRANKS
Goldman Sachs Keeps Their Buy Rating on Tango Therapeutics (TNGX)AUGUST 7, 2023TIPRANKS
Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business HighlightsAUGUST 7, 2023TIPRANKS
Tango Therapeutics reports Q2 EPS (23c), consensus (34c)AUGUST 7, 2023TIPRANKS
👍️0

Your Recent History

NASDAQ
TNGX
Tango Therapeutics
DOWI
DJSESD
DJ Sweden Select Dividen...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads